Status:
NOT_YET_RECRUITING
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
Lead Sponsor:
Shanghai Henlius Biotech
Conditions:
CRC
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized ...
Eligibility Criteria
Inclusion
- Age\>=18Y and ≤75Y
- Good Organ Function
- Expected survival time ≥ 3 months
- mCRC that have been diagnosed histologically
- KRAS/NRAS/BRAF WT verified by PCR or NGS of tumor tissue
- ECOG score 0-1;
Exclusion
- HIV infection
- Active clinical severe infection;
- A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.
Key Trial Info
Start Date :
July 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 15 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05239650
Start Date
July 15 2022
End Date
October 15 2026
Last Update
May 3 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.